CryoPort

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Brentwood, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CryoPort achieves record revenue, eyes growth in cell therapy logistics

CryoPort's Q4 2022 performance reflects robust revenue growth and strategic investments, positioning the company for further expansion in cell and gene therapy logistics.
While facing challenges in manufacturing capacity and supply chain, CryoPort's focus on revenue diversification and margin improvement initiatives strengthens its competitive position.
The company's outlook for 2023 is optimistic, with opportunities in supporting commercial therapies, market share expansion, and new product launches driving growth.

CryoPort (CYRX) reports strong Q1 revenue growth and eyes global expansion

CryoPort's Q1 performance reflects robust revenue growth and strategic advancements in logistics solutions.
While facing industry challenges and capacity constraints, CryoPort is leveraging opportunities for expansion and innovation.
The company's focus on acquisitions, partnerships, and market growth positions it well for future success.
Investments in capabilities and global expansion underscore CryoPort's commitment to driving revenue and operational excellence.

CryoPort reports Q2 revenue impact from China, remains confident in growth

CryoPort faces challenges from China's economic conditions but remains confident in its long-term growth drivers in the cell and gene therapy industry.
Strategic investments in technology, premium product positioning, and operational enhancements are key strengths driving future growth and competitiveness.
Navigating short-term challenges, seizing expansion opportunities, and leveraging synergies with MVE in China are crucial for CryoPort's future success.

CryoPort reports robust Q3 earnings, eyes growth in life sciences

CryoPort's Q3 results met expectations, showcasing growth in revenue and execution of its corporate strategy for long-term profitability.
The company's performance reflects strong demand, strategic acquisitions, and a focus on innovation and customer service.
While facing challenges like manufacturing capacity and rising costs, CryoPort remains well-positioned to capitalize on market opportunities.
With a clear outlook for future growth and a stable financial position, CryoPort is poised for continued success in the life sciences industry.

CryoPort reports strong revenue, eyes cell therapy growth in 2024

CryoPort's FY 2023 performance driven by service revenue and global clinical trial support.
Focused on revenue growth in cell and gene therapy industry, introducing innovative products.
Addressing challenges in market competition, revenue trends, and debt management.
Positioned for progressive advancement in 2024, capitalizing on market opportunities.

Cryoport maintains revenue guidance amidst challenges, eyes growth opportunities

Cryoport maintains revenue guidance despite Q1 challenges, focusing on growth drivers and cost-saving measures for improved financial performance.
Strong cash balance, collaborations with logistics companies, and ongoing revenue growth initiatives position Cryoport for future success.
Challenges in MVE business and biologistics revenue softness require attention, but opportunities lie in financial improvement and revenue growth drivers.
Anticipation of continuous progression in the second half and positive integration with CRYOPDP highlight growth prospects for Cryoport.

CryoPort reports strong Q2 revenue growth, eyes profitability by 2025

CryoPort's Q2 2024 performance reflects robust revenue growth and cost-saving initiatives.
While facing challenges in soft demand and market conditions, the company eyes growth opportunities.
Confidence in revenue guidance and proactive measures signal a strategic path to profitability.
Strengthening commercial revenue and upcoming facility openings position CryoPort for future growth.

CryoPort reports Q3 growth, focuses on profitability and cost reduction

CryoPort's Q3 performance showcased growth in Life Sciences Services and strategic initiatives to drive profitability.
Despite challenges in the life sciences sector and uneven market recovery in MVE division, CryoPort remains focused on cost reduction and long-term growth.
Opportunities lie in new product launches, high-value contract acquisitions, and maintaining financial strength post-election.
Overall, CryoPort's resilience and strategic focus position the company for sustained growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

JOHNSON CITY, Tenn. and NASHVILLE, Tenn.

LabConnect and Cryoport Partner to Provide Support for Innovative Triumvira Cell and Gene Therapy Clinical Trial

Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q1 2021 Results - Earnings Call Transcript

NASHVILLE, Tenn., May 4, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three-month period ended March 31, 2021.

Cryoport Revenue Climbs to $53.3 Million for First Quarter 2021

NASHVILLE, Tenn., April 27, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the first quarter ended March 31, 2021 on Tuesday, May 4, 2021 after U.S. markets close.

Cryoport to Report First Quarter 2021 Financial Results on May 4, 2021

In the past few years, the CAR-T, gene-based, regenerative medicines sector is becoming prominent.

Cryoport: Once In A Lifetime Opportunity

New York, New York--(Newsfile Corp. - April 8, 2021) - Levi & Korsinsky announces it has commenced an investigation of Cryoport, Inc. (NASDAQ: CYRX) concerning possible breaches of fiduciary duty. To obtain additional information, go to: https://www.zlk.com/compensation2/cryoport-inc-information-request-form or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cryoport, Inc. (CYRX)

NASHVILLE, Tenn., April 6, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced it has acquired Critical Transport Solutions Australia Pty Ltd  ("CTSA"), a market leader in providing premium healthcare logistics management services, specializing in time- and temperature-critical solutions for the medical and pharmaceutical industries based in Australia, for approximately USD 5 million.

Cryoport Acquires Temperature-Controlled Logistics Provider in Australia

The stock price of CryoPort, a provider of cold chain logistics solutions for biopharmaceutical companies, has seen a large 22% drop over the last five trading days, but we believe the stock, after the recent drop, may trend higher in the near term. The recent drop can largely be attributed to.

Can CryoPort Stock Rebound After A Recent 22% Drop?

NASHVILLE, Tenn., March 3, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has elected Linda Baddour as a member of the...

Cryoport Announces Appointment of Linda Baddour to its Board of Directors

Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q4 2020 Results - Earnings Call Transcript

NASHVILLE, Tenn., March 1, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three- and twelve-month periods ended...

Cryoport Reports Record Results for Full Year 2020

NASHVILLE, Tenn., Feb. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the fourth...

Cryoport to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 1, 2021

NASHVILLE, Tenn., Feb. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced the launch of its Environmental, Social & Governance (ESG)...

Cryoport Launches Environmental, Social, and Governance (ESG) Program

NASHVILLE, Tenn., Jan. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced the closing of an underwritten public offering of 4,356,059 shares...

Cryoport Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters to Purchase Additional Shares

NASHVILLE, Tenn., Jan. 20, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced the pricing of its underwritten public offering of an aggregate of...

Cryoport Announces Pricing of Public Offering of Common Stock

NASHVILLE, Tenn., Jan. 19, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that it intends to offer $200 million of shares of common stock in...

Cryoport Announces Proposed Public Offering of Common Stock

BioCryst Pharmaceuticals

Both stocks are in the early stage of a long-term growth trajectory.

2 Ultra-High-Growth Healthcare Stocks That Are Just Getting Started

With the approval of Yescarta and Kymriah in recent years, you are now seeing unprecedented growth in the CAR-T industry. Logistic providers that support CAR-T and gene therapies are profiting from this fundamental industry tailwind.

Cryoport: Mega Growth Ahead

Cryoport is a strong cold chain platform focused on the fast-growing cell and gene therapy end-market. Company has demonstrated strong execution through COVID and, with recent acquisitions, will become the largest pure-play in the sector.

Cryoport: Strong Cold Chain Play At A Reasonable Valuation

Cryoport's operating model remains insulated via key differentiators in the thermoregulatory logistics domain, with cloud-based integration along the audit chain. Linking with larger players in providing commercial support gives the ability to generate long-tailed asset returns for value creation.

Cryoport: Insulated Portfolio In Thermoregulatory Logistics Creates Long-Tailed Asset Value

Avantor Inc.

McKesson

Thermo Fisher Scientific

Excited about the Covid-19 vaccines from Pfizer and Moderna? You'll be waiting a long time unless the vaccines can be shipped at 94 degrees below zero.

Ultra-Cold Freezer Makers To Profit From Covid-19 Vaccine Rush

Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q3 2020 Results - Earnings Call Transcript

NASHVILLE, Oct. 29, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in life sciences solutions, today announced that the Company will report financial results for the third quarter ended September 30, 2020 on Thursday, November 5, 2020...

Cryoport to Report Third Quarter 2020 Financial Results on November 5, 2020

NASHVILLE, Tenn., Oct. 1, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), the life sciences industry's preeminent partner for temperature-controlled supply chain solutions, today announced it has completed the acquisitions of MVE Biological Solutions...

Cryoport Completes Acquisitions of MVE Biological Solutions and CRYOPDP

Cryoport is acquiring Chart's cryobiological business and getting a big boost from one of the giants in private equity.

News for CryoPort Stock (CYRX)